Skip to main content

$0.075 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
5 June 2026 at 5:54am
Register to track PAA and receive email alerts.

Phase IIb Canine Trial Identifies Therapeutic Window for MPL

StockBot

416,823 posts

PAA released this announcement to the ASX on 27 April 2021, 8:30. The announcement is marked as price sensitive, and is 1 page(s) in length and 367.01kb in size.

You can view all announcements from PAA and see how they appear on a price chart on the announcements page.

At the date of this announcement, PAA was 0.018% short sold according to ASIC data. It was ranked the 542nd most shorted stock on the ASX. It is now ranked as the 492nd most shorted stock on the ASX with 0.022% of total shares short sold as of the latest reported data (11 October 2024).

Other Recent Announcements from PAA
Results of General Meeting 30 June 2023, 12:38
Trading Halt 30 June 2023, 9:48
General Meeting - Chairman Script 30 June 2023, 9:42
Phase IIb Canine Trial Identifies Therapeutic Window for MPL 27 April 2021, 8:30
Epichem OHD Presentation - Waste to Fuels Technology 21 April 2021, 8:58
PharmAust Receives $750k R&D Tax Incentive Refund 8 April 2021, 8:25
Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity 7 April 2021, 9:41
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track PAA and receive email alerts.